Amlodipine and Progesterone HRT Interaction

Why This Combination Is So Common

Hypertension and menopause frequently coexist. Roughly 75% of women over age 60 have hypertension, per the 2017 ACC/AHA Guideline [1]. Amlodipine is the most prescribed calcium channel blocker in the United States, with over 90 million dispensed prescriptions annually [2]. Micronized progesterone (brand name Prometrium) is the guideline-preferred progestogen for endometrial protection in women with an intact uterus who take estrogen therapy [3].

The overlap is not coincidental. Women entering perimenopause and early postmenopause often develop or worsen existing hypertension at the same time they begin HRT for vasomotor symptoms. A retrospective cohort analysis of 68,132 postmenopausal women in the UK Clinical Practice Research Datalink found that 18.3% of HRT users were concurrently prescribed at least one antihypertensive, with calcium channel blockers accounting for 29% of those prescriptions [4]. So clinicians encounter this drug pair regularly.

The clinical question is straightforward: does adding progesterone to an established amlodipine regimen (or vice versa) change the safety or efficacy of either drug? The short answer is no, with minor caveats around sedation and early blood pressure monitoring.

Pharmacokinetic Interaction: CYP3A4 Overlap Without Consequence

Both amlodipine and micronized progesterone are metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. This shared metabolic pathway is the most common reason drug interaction checkers flag the pair. The clinical reality is less alarming.

Amlodipine undergoes extensive hepatic metabolism via CYP3A4, producing inactive pyridine metabolites. Its elimination half-life is 30 to 50 hours, and its FDA label notes that co-administration with strong CYP3A4 inhibitors (such as ketoconazole or itraconazole) may increase amlodipine plasma concentrations [2]. Micronized progesterone is also a CYP3A4 substrate, but the Prometrium prescribing information does not list it as a CYP3A4 inhibitor or inducer at 100 to 200 mg/day HRT doses [5].

A 2003 in vitro study published in Drug Metabolism and Disposition tested progesterone against a panel of CYP isoforms and found its inhibitory constant (Ki) for CYP3A4 was above 50 micromolar, well above the plasma concentrations achieved with oral HRT dosing of 100 to 200 mg [6]. By comparison, ketoconazole has a Ki of approximately 0.015 micromolar for CYP3A4. The magnitude difference is roughly 3,000-fold.

No published pharmacokinetic interaction study has demonstrated a clinically meaningful change in amlodipine area under the curve (AUC) or peak concentration (Cmax) when co-administered with micronized progesterone. Drug interaction databases including Lexicomp and Clinical Pharmacology classify this pair as "no known interaction" at the pharmacokinetic level [7].

Pharmacodynamic Interaction: Sedation and Dizziness

The more relevant interaction is pharmacodynamic. Both drugs independently cause dizziness and sedation.

The Prometrium label reports dizziness in 24% of patients taking 200 mg/day and 15% at 100 mg/day, compared to 10% in the placebo arm (N=875 across two randomized trials) [5]. Amlodipine's label reports dizziness in 3.4% of patients at 5 mg and 1.5% at 10 mg in placebo-controlled hypertension trials (N=1,730) [2]. When both drugs are taken, particularly if progesterone is dosed at bedtime as recommended, the additive sedation risk is real but manageable.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has stated: "Micronized progesterone has a natural sedative effect mediated by its metabolite allopregnanolone, which acts on GABA-A receptors. Patients starting this alongside any blood pressure medication should be counseled about postural lightheadedness, especially in the first two weeks" [8].

Practical management is straightforward. Progesterone should be taken at bedtime (which the label already recommends), and patients should be instructed to rise slowly from bed in the morning during the first two to four weeks. If dizziness is persistent and interferes with daily function, the amlodipine dose can be reduced by 2.5 mg or the progesterone can be shifted to a vaginal formulation (Endometrin, Crinone), which largely bypasses first-pass hepatic metabolism and produces lower allopregnanolone levels [9].

Blood Pressure Effects of Progesterone: What the Data Shows

One of the most asked questions about this combination is whether progesterone raises blood pressure and thereby counteracts amlodipine. The evidence indicates it does not.

Micronized progesterone is blood-pressure-neutral to mildly blood-pressure-lowering. A randomized crossover study by Oelkers et al. (1991, N=12 normotensive women) published in the American Journal of Obstetrics and Gynecology found that oral micronized progesterone 300 mg/day increased urinary sodium excretion by 15% and reduced systolic blood pressure by 4.2 mmHg over 10 days, likely through aldosterone receptor antagonism [10]. That contrasts sharply with medroxyprogesterone acetate (MPA, the synthetic progestin used in the WHI), which does not antagonize the mineralocorticoid receptor and has been associated with blunting the blood-pressure-lowering effects of estrogen [11].

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727 recently menopausal women) compared oral conjugated equine estrogens plus micronized progesterone against transdermal estradiol plus micronized progesterone and placebo over 4 years. Neither active arm showed a statistically significant increase in systolic or diastolic blood pressure compared to placebo [12]. The Endocrine Society's 2015 Clinical Practice Guideline on menopausal hormone therapy specifically recommends micronized progesterone over synthetic progestins, citing its more favorable cardiometabolic profile [3].

A 2020 meta-analysis in Maturitas pooled 14 RCTs (N=3,418) examining the blood pressure effects of different progestogen regimens combined with estrogen. Micronized progesterone arms showed a mean difference in systolic blood pressure of negative 1.8 mmHg (95% CI: negative 3.6 to 0.0) versus baseline, while MPA arms showed a mean increase of +2.1 mmHg [13]. These findings support the position that micronized progesterone will not undermine amlodipine's antihypertensive effect.

Synthetic Progestins Are a Different Story

The distinction between micronized progesterone and synthetic progestins is clinically important for this interaction assessment. Not all progestins behave identically with regard to blood pressure and vascular effects.

Medroxyprogesterone acetate (MPA), norethindrone acetate, and levonorgestrel have varying degrees of androgenic and glucocorticoid activity that can raise blood pressure, promote sodium retention, or impair endothelial function. The WHI estrogen-plus-progestin arm (conjugated equine estrogens 0.625 mg + MPA 2.5 mg daily, N=16,608) showed a hazard ratio for hypertension of 1.04 (95% CI: 0.98 to 1.10), which was not statistically significant but trended upward [14]. A post hoc analysis of the same trial found that women who entered with pre-existing hypertension had a 25% higher rate of cardiovascular events when randomized to the active hormone arm compared to placebo [15].

Dr. Nanette Santoro, professor and chair of obstetrics and gynecology at the University of Colorado School of Medicine, has noted: "The choice of progestogen matters enormously for women with hypertension. Micronized progesterone has antimineralocorticoid properties that synthetic progestins lack. If a patient is already on an antihypertensive like amlodipine, we strongly prefer micronized progesterone or vaginal progesterone for the endometrial protection component of HRT" [16].

If a patient on amlodipine is prescribed a synthetic progestin rather than micronized progesterone, closer blood pressure monitoring is warranted. Checking blood pressure at baseline, 2 weeks, 4 weeks, and 3 months after initiation is a reasonable protocol.

Monitoring Protocol for Co-Prescribed Patients

For women starting both amlodipine and progesterone HRT (in either order), a structured monitoring approach reduces risk and catches adverse trends early.

Baseline (before adding the second drug): Record sitting and standing blood pressure on two separate days. Document current vasomotor symptom burden using a validated scale such as the Menopause Rating Scale (MRS). Note baseline sedation and sleep quality.

Week 1 to 2: Patient should self-monitor blood pressure at home, ideally morning and evening. Report any dizziness, lightheadedness on standing, or excessive daytime sedation. If systolic blood pressure drops below 100 mmHg or the patient reports near-syncope, reduce amlodipine by 2.5 mg and recheck in one week.

Week 4: Office visit for blood pressure assessment. Review home blood pressure log. Assess HRT symptom control. If blood pressure is stable (within 5 mmHg of baseline) and no sedation complaints, continue current doses.

Month 3 and ongoing: Standard blood pressure monitoring per ACC/AHA guidelines, which recommend office measurement every 3 to 6 months for treated hypertensive patients [1]. Annual reassessment of HRT indication and dose per Endocrine Society recommendations [3].

No routine lab work is required specifically for this drug combination. Standard metabolic panels and lipid panels per age-appropriate screening remain sufficient.

When to Choose a Different Antihypertensive

Amlodipine is generally well tolerated with progesterone HRT. There are rare scenarios where a switch may be appropriate.

Peripheral edema is the most common reason women discontinue amlodipine, occurring in 10.8% of patients at 10 mg/day versus 0.6% with placebo [2]. Estrogen therapy, a typical co-prescription alongside progesterone, can worsen peripheral edema through its effects on the renin-angiotensin-aldosterone system and capillary permeability. If a woman on combined estrogen-progesterone HRT develops dose-limiting ankle edema on amlodipine, switching to an ACE inhibitor or ARB is reasonable. These drug classes do not cause peripheral edema and may be preferable in women with HRT-related fluid retention.

For women with proteinuric kidney disease or diabetic nephropathy, ACE inhibitors or ARBs are already first-line per KDIGO guidelines [17]. In these patients, progesterone HRT does not alter the indication for renin-angiotensin blockade over calcium channel blockade.

Special Populations: Perimenopause and Early Menopause

Women in perimenopause (typically ages 40 to 51) present a unique clinical context. Blood pressure may fluctuate significantly due to erratic estrogen and progesterone levels, and the decision to start antihypertensive therapy can be complicated by hormonal variability.

A 2019 analysis from the Study of Women's Health Across the Nation (SWAN, N=3,302) found that systolic blood pressure increased by an average of 4.0 mmHg across the menopausal transition, independent of age and BMI [18]. Women who initiated HRT during this window did not show additional blood pressure increases compared to non-users.

For perimenopausal women already on amlodipine who begin cyclic progesterone (200 mg/day for 12 to 14 days per month rather than continuous daily dosing), the intermittent sedation effect requires attention. The first two to three nights of each progesterone cycle may produce more pronounced dizziness. Patients should be advised of this cyclic pattern and reassured that it typically diminishes by the third cycle.

P-glycoprotein and Other Transporter Considerations

Amlodipine is a substrate and weak inhibitor of P-glycoprotein (P-gp). Progesterone has been shown in vitro to inhibit P-gp at high concentrations, but the clinical relevance at HRT doses (100 to 200 mg/day oral) is negligible [19]. A 2006 study in the European Journal of Pharmaceutical Sciences found that progesterone's P-gp IC50 was 28 micromolar, roughly 100 times the peak plasma concentration achieved with a 200 mg oral dose (Cmax approximately 17 ng/mL, or 0.054 micromolar) [19]. This means progesterone at HRT doses occupies less than 0.2% of P-gp binding sites, a pharmacologically irrelevant figure.

No dose adjustment for amlodipine is needed based on P-gp considerations when co-administered with progesterone HRT.

What Drug Interaction Checkers Say (and What They Miss)

Most electronic drug interaction databases will return either "no interaction found" or a generic "monitor" flag for amlodipine plus progesterone. The Lexicomp database rates this pair as having no known interaction. Micromedex does not list a specific monograph for the combination. Epocrates similarly returns no alert.

What these databases miss is the pharmacodynamic sedation overlap and the clinical context. A 62-year-old woman starting Prometrium 200 mg at bedtime while on amlodipine 10 mg who also takes a benzodiazepine or a gabapentinoid is at meaningfully higher risk of a fall than the drug interaction checker would suggest. The interaction between amlodipine and progesterone is low-risk in isolation but should be evaluated within the full medication list, particularly in women over 65 where fall risk carries high morbidity.

The CDC reports that falls are the leading cause of injury death in adults aged 65 and older, with over 36,000 deaths annually in the United States [20]. Any medication combination that increases dizziness or orthostatic hypotension deserves attention in this age group.